[A Multi-Center Clinical Trial of Qianlieantong Tablets for Chronic Prostatitis].

Kai Guo,Ming-Xing Qiu,Song-Liang Cai,Jing Leng,Yin-Fa Han,Guo-Xing Shao,Chuan-Hang Wang,Xiang-An Tu,Luo-Yan Yang,Ge-Ming Chen,Qiang Zhou,Yong Deng,Xiao-Long Wang
DOI: https://doi.org/10.3969/j.issn.1009-3591.2007.10.023
2007-01-01
Abstract:OBJECTIVE:To observe the efficacy and safety of Qianlieantong Tablets in the treatment of chronic prostatitis.METHODS:A multi-center, self-controlled open clinical trial was conducted. A total of 280 subjects with chronic prostatitis were enrolled and treated by Qianlieantong Tablets, 3 times a day, 5 tablets each time. Before and after 2 and 4 weeks after the administration, NIH-CPSI scores and white blood cell counts in the prostate secretion were recorded.RESULTS:Of the 273 subjects evaluated, the rates of excellence, effectiveness and ineffectiveness were 35.2% (n = 96), 47.6% (n = 130) and 17.2% (n = 47), respectively, with a total effectiveness rate of 82.8%. After 4 weeks'medication, the scores of the subjects on NIH-CPSI pain, voiding and quality of life and white blood cell counts in prostate secretion were significantly decreased compared with pre-treatment (P < 0.01). No adverse events or laboratory abnormality related to the medication were observed.CONCLUSION:Qianlieantong Tablets has a significant effect on chronic prostatitis with high safety, particularly indicated in chronic prostatitis with pelvic pain.
What problem does this paper attempt to address?